Novel Oral Anticoagulants for Stroke Prophylaxis and Venous Thromboembolism Prevention and Treatment
Publication Date
8-14-2015
Keywords
novel oral anticoagulants, atrial fibrillation, deep vein thrombosis, pulmonary embolism, dabigatran, Pradaxa, rivaroxaban, Xarelto, apixaban, Eliquis, edoxaban, Savaysa, Lixiana
Abstract
Novel oral anticoagulants (NOACs) are becoming popular management options for stroke prophylaxis in nonvalvular atrial fibrillation as well as deep vein thrombosis and pulmonary embolism treatment and prophylaxis. NOACs have similar efficacy to warfarin along with noninferior safety profiles. Patient comorbidities, size, renal and hepatic function, and concomitant drug regimen play a role in which NOAC a physician may choose.
Recommended Citation
Alsayegh LG. Novel oral anticoagulants for stroke prophylaxis and venous thromboembolism prevention and treatment. J Patient-Centered Res Rev. 2015;2:139-146. doi: 10.17294/2330-0698.1055
Included in
Cardiology Commons, Cardiovascular Diseases Commons, Cardiovascular System Commons, Chemicals and Drugs Commons
Submitted
March 24th, 2015
Accepted
June 2nd, 2015
